Literature DB >> 32380518

Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy.

Haiyan Zheng1, James M S Wason1,2.   

Abstract

Basket trials have emerged as a new class of efficient approaches in oncology to evaluate a new treatment in several patient subgroups simultaneously. In this article, we extend the key ideas to disease areas outside of oncology, developing a robust Bayesian methodology for randomized, placebo-controlled basket trials with a continuous endpoint to enable borrowing of information across subtrials with similar treatment effects. After adjusting for covariates, information from a complementary subtrial can be represented into a commensurate prior for the parameter that underpins the subtrial under consideration. We propose using distributional discrepancy to characterize the commensurability between subtrials for appropriate borrowing of information through a spike-and-slab prior, which is placed on the prior precision factor. When the basket trial has at least three subtrials, commensurate priors for point-to-point borrowing are combined into a marginal predictive prior, according to the weights transformed from the pairwise discrepancy measures. In this way, only information from subtrial(s) with the most commensurate treatment effect is leveraged. The marginal predictive prior is updated to a robust posterior by the contemporary subtrial data to inform decision making. Operating characteristics of the proposed methodology are evaluated through simulations motivated by a real basket trial in chronic diseases. The proposed methodology has advantages compared to other selected Bayesian analysis models, for (i) identifying the most commensurate source of information and (ii) gauging the degree of borrowing from specific subtrials. Numerical results also suggest that our methodology can improve the precision of estimates and, potentially, the statistical power for hypothesis testing.
© The Author 2020. Published by Oxford University Press.

Entities:  

Keywords:  Basket trials; Hellinger distance; Hierarchical models; Precision medicine; Robustness

Mesh:

Year:  2022        PMID: 32380518      PMCID: PMC8759447          DOI: 10.1093/biostatistics/kxaa019

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  27 in total

1.  Addressing potential prior-data conflict when using informative priors in proof-of-concept studies.

Authors:  Timothy Mutsvari; Dominique Tytgat; Rosalind Walley
Journal:  Pharm Stat       Date:  2015-11-16       Impact factor: 1.894

2.  Methods of joint evaluation of efficacy and toxicity in phase II clinical trials.

Authors:  Caroline Tournoux; Yann De Rycke; Jacques Médioni; Bernard Asselain
Journal:  Contemp Clin Trials       Date:  2007-01-27       Impact factor: 2.226

Review 3.  Definitions and statistical properties of master protocols for personalized medicine in oncology.

Authors:  Lindsay A Renfro; Sumithra J Mandrekar
Journal:  J Biopharm Stat       Date:  2017-10-09       Impact factor: 1.051

4.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.

Authors:  Brian P Hobbs; Daniel J Sargent; Bradley P Carlin
Journal:  Bayesian Anal       Date:  2012-08-28       Impact factor: 3.728

5.  A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials.

Authors:  Haiyan Zheng; Lisa V Hampson; Simon Wandel
Journal:  Stat Methods Med Res       Date:  2019-01-16       Impact factor: 3.021

6.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

7.  RECIST 1.1-Update and clarification: From the RECIST committee.

Authors:  Lawrence H Schwartz; Saskia Litière; Elisabeth de Vries; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Lesley Seymour
Journal:  Eur J Cancer       Date:  2016-05-14       Impact factor: 9.162

Review 8.  Bayesian designs to account for patient heterogeneity in phase II clinical trials.

Authors:  Peter F Thall; J Kyle Wathen
Journal:  Curr Opin Oncol       Date:  2008-07       Impact factor: 3.645

9.  Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.

Authors:  Scott M Berry; Kristine R Broglio; Susan Groshen; Donald A Berry
Journal:  Clin Trials       Date:  2013-08-27       Impact factor: 2.486

10.  Adaptive adjustment of the randomization ratio using historical control data.

Authors:  Brian P Hobbs; Bradley P Carlin; Daniel J Sargent
Journal:  Clin Trials       Date:  2013       Impact factor: 2.486

View more
  3 in total

1.  Bridging across patient subgroups in phase I oncology trials that incorporate animal data.

Authors:  Haiyan Zheng; Lisa V Hampson; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2021-01-27       Impact factor: 3.021

2.  Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.

Authors:  Alexander Kaizer; Emily Zabor; Lei Nie; Brian Hobbs
Journal:  PLoS One       Date:  2022-08-02       Impact factor: 3.752

3.  Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential.

Authors:  Michael J Grayling; Theophile Bigirumurame; Svetlana Cherlin; Luke Ouma; Haiyan Zheng; James M S Wason
Journal:  BMC Rheumatol       Date:  2021-07-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.